Global Minimal Residual Disease (MRD) Testing Market Size & Trends Report Segmented by Offering (Assay Kits/Reagents, Instruments, Services), Technology (PCR, NGS), Application (Haematological Malignancies, Solid Tumours), End-user (Hospitals, Specialty Clinics), & Regional Forecast to 2031

Minimal residual disease (MRD) testing is an advanced method of diagnosing and monitoring cancer, using precise diagnostics, to determine whether there are residual cancer cells still present in the body following therapy. These residual cancer cells can remain undetected by standard techniques but may eventually cause relapse if not detected early. minimal residual disease testing utilizes advanced technologies, such as next generation sequencing, polymerase chain reaction (PCR), and multiparameter flow cytometry, among others, to provide deep detection levels. MRD is routinely performed in patients with hematologic malignancies to evaluate treatment response, direct further treatments, provide an estimate of prognosis, and tailor individual treatment plans for each patient.

Rising burden of cancer to propel market demand

The rising global burden of cancer, particularly hematologic malignancies such as leukemia, lymphoma, and multiple myeloma, is a key driver of the minimal residual disease testing market. According to GLOBOCAN 2022, hematologic malignancies accounted for 6.6% of total cancer cases and 7.2% of total cancer-related deaths worldwide in 2022. Hematologic cancers arise in the blood and bone marrow (leukemia) and in the lymphatic system (lymphoma) where disease progression and relapse often occur because of the presence of small numbers of residual malignant cells remaining after treatment. With rates of incidence increasing globally due to an aging population, poor lifestyle choices, and advances in diagnostic technologies, the need for more accurate monitoring methods like minimal residual disease testing is becoming critical.

In patients with hematologic malignancies, achieving a complete remission does not guarantee that the underlying disease has been eliminated completely; hence, patients may appear to have no signs of disease using traditional imaging or morphological assessments, yet very low levels of malignant cells may still exist and eventually lead to relapsed disease. MRD testing addresses this limitation of traditional treatment monitoring by providing an ability to detect the residual cancer cells present in metaphase and therefore identify patients at high risk for recurrence. minimal residual disease testing provides an objective means of measuring whether a patient is likely to experience disease recurrence post-remission and, consequently, is a useful method to evaluate treatment response and risk for recurrence.

The increase in hematologic malignancies has created an increased demand for personalized treatment approaches where MRD status can determine treatment decisions in cancer care. Physicians can use MRD results to adjust therapy intensity, determine the need for stem cell transplantation, or evaluate the effectiveness of targeted therapies and immunotherapies, causing MRD testing to become part of standard care protocols across oncology.

The growing volume of patients diagnosed with hematologic malignancies has created a greater need for diagnostic testing and long-term disease monitoring resulting in an expanding minimal residual disease testing market. Hence, many healthcare systems are implementing MRD based monitoring to improve patient outcomes, decrease the number of relapses, and reduce the cost of treatment. Additionally, with increasing research activity and clinical trials related to hematologic malignancies incorporating MRD as a primary endpoint in the development of new therapies, this is likely to continue to drive greater adoption of MRD testing. Overall, the increasing burden of hematologic cancers has created a sustainable demand for advanced MRD testing solutions.

To learn more about this report, download the PDF brochure

Shift toward precision medicine is driving the market growth

One of the most important contributors to the minimal residual disease testing market growth is the growing use of precision medicine. Precision medicine is a personalized form of treatment that uses specific information about a patient's genetics, molecular biology, and other disease factors to formulate a tailored treatment plan based on their unique biology, as opposed to applying the conventional one size fits all treatment plan used for all other patients.  It uses extensive biological information related to the patient to optimize therapy selection, timing, and intensity. The role of MRD testing is central to this approach, since it provides highly sensitive, personalized/myogenic information about whether a patient has residual cancer after therapy.

Minimal residual disease (MRD) testing status has become an essential biomarker for personalized treatment guidance in oncology, particularly for hematological cancers. By accurately quantifying residual disease at very low levels, MRD testing enables clinicians to evaluate the efficacy of therapy and determine the most appropriate course of action for a patient concerning whether they need to modify their treatment plan. For example, patients with an undetectable MRD could reduce their therapy regimen's intensity, reducing the risk of toxicity and improving their quality of life. In contrast, patients with detectable MRD need to increase their therapy intensity or use a different treatment strategy to avoid recurrence.

MRD testing also permits risk stratification i.e., classifying patients into different groups based on their relative risk of relapse, thereby providing clinicians with an additional tool for making an informed decision about long-term management, maintenance therapy and follow-up frequency. The current shift to value-based care within healthcare systems makes the ability of MRD testing to improve treatment outcomes while minimizing unnecessary interventions further contributing to the role of precision medicine.

Overall, the trend towards precision medicine is accelerating MRD testing adoption and demonstrating its value as an essential tool for individualized cancer care, improving prognostication and providing tools for better therapeutic decision-making.

To learn more about this report, download the PDF brochure

Application Segment Outlook

Hematological malignancies represent the largest segment in the MRD testing market, since MRD testing has established clinical utility in blood cancers (leukemia and lymphoma) and is widely used clinically for monitoring response to therapy and detecting relapse. Solid tumors represent the fastest growing segment of the MRD testing market, and this is primarily due to increasing technological advancement in liquid biopsy technologies as well as growing research focused on circulating tumor DNA (ctDNA)-based MRD detection. The expansion of clinical usage, increased evidence supporting the use of MRD testing for solid tumor applications, and the increasing incidence of non-invasive testing are all contributing factors to the rapid growth of the solid tumor segment of the MRD testing market.

North America leads MRD adoption due to research strength & reimbursement support; APAC growth driven by patient volume & infrastructure expansion

North America held the largest share of the minimal residual disease (MRD) testing market primarily due to, an advanced healthcare system, significant commitment to precision medicine, high presence of leading MRD testing companies, and favourable reimbursement policies; as well as the region’s historical strength in clinical research activities, with many of their laboratories performing NGS and liquid biopsy. The Asia Pacific region is estimated to be the fastest growing segment largely because of the rising number of cancer diagnoses, improvements to healthcare infrastructure, increasing funding to diagnostic laboratories, and an increasing awareness to detect diseases earlier. The ability to access advanced diagnostic testing combined with a very large number of patients relative to North America, helps contribute to the overall growth of the MRD testing market in the Asia Pacific region.

Competitive Landscape Analysis

The global minimal residual disease testing market is marked by the presence of established and emerging market players such as F. Hoffmann-La Roche Ltd (Switzerland); Labcorp (US); Guardant Health, Inc. (US); Adaptive Biotechnologies (US); Natera, Inc. (US); Exact Sciences Corporation (US); QIAGEN (the Netherlands); Bio-Rad Laboratories (US), Inc.; Sysmex Corporation (Japan); and Thermo Fisher Scientific Inc. (US); among others. Some of the key strategies adopted by market players include new product and service launches and approvals, acquisitions, and strategic partnerships, agreements, and collaborations.

Get a sample report for competitive landscape analysis

Growth strategies adopted by players to establish their foothold in the market

Players operating in this market are adopting various growth strategies such as new product and service launches and approvals, acquisitions, and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

• In March 2026, Myriad Genetics launched its Precise MRD test with select oncology practices, introducing a tumor-informed ctDNA assay for breast cancer monitoring. This development marks a step toward broader commercialization, enabling ultra-sensitive detection and personalized, longitudinal cancer monitoring to guide treatment decisions
• In January 2026, Labcorp expanded its MRD testing portfolio with Plasma Detect ID and Genome tests to monitor recurrence risk in breast, lung, and colon cancers using ctDNA-based liquid biopsy. These advancements enable earlier detection of cancer recurrence and support more personalized, non-invasive monitoring and treatment decision-making
• In June 2025, QIAGEN expanded its MRD testing portfolio through partnerships with Tracer Biotechnologies and Foresight Diagnostics to advance liquid biopsy and NGS-based assays across solid tumors and lymphoma. These collaborations strengthen its capabilities in decentralized, non-invasive MRD testing and support pharma clinical trials and companion diagnostics development
• In January 2025, Adaptive Biotechnologies and NeoGenomics entered a strategic collaboration to expand access to personalized MRD monitoring for blood cancer patients using clonoSEQ integrated with COMPASS and CHART services. This partnership enhances longitudinal disease tracking and supports more personalized treatment decisions by combining advanced NGS-based MRD testing with comprehensive oncology assessment services
• In February 2024, Veracyte acquired C2i Genomics to enhance its diagnostics platform with AI-driven, whole-genome MRD capabilities. This acquisition expands its role across the cancer care continuum, enabling advanced disease monitoring, recurrence detection, and personalized oncology insights
• In April 2023, Quest Diagnostics acquired Haystack Oncology to strengthen its MRD capabilities through advanced ctDNA-based liquid biopsy technology. This acquisition enhances personalized cancer monitoring and expands access to highly sensitive MRD testing for improved recurrence detection and treatment guidance

Report Scope

Global Minimal Residual Disease (MRD) Testing Market Segmentation

This report by Medi-Tech Insights provides the size of the global MRD testing market at the regional- and country-level from 2024 to 2031. The report further segments the market based on offering, technology, application, and end user.

Market Size & Forecast (2024-2031), By Offering, USD Billion

• Assay Kits & Reagents
• Instruments
• Services  

Market Size & Forecast (2024-2031), By Technology, USD Billion

• Polymerase Chain Reaction (PCR)
• Next-generation Sequencing (NGS)
• Flow Cytometry
• Other Technologies

Market Size & Forecast (2024-2031), By Application, USD Billion

• Haematological Malignancies
  • Leukaemia
  • Lymphoma
• Solid Tumours
• Multiple Myeloma
• Other Applications

Market Size & Forecast (2024-2031), By End User, USD Billion

• Hospitals & Specialty Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Other End Users

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Reports:

Global Cancer Biomarkers Market Size, Share & Industry Analysis Report By Type (Breast, Prostate, Colon, Thyroid), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, Technology, and Region Forecasts, 2026–2031

Global Multi Cancer Early Detection Market Size, Share, Growth & Trends Report Segmented by Type (Liquid Biopsy, Gene Panel, LDT), End-user (Hospitals, Diagnostic Centers, Others) Industry Analysis & Regional Forecast to 2030

Global Interventional Oncology Market Size & Trends Report Segmented by Technique (Ablation Therapies, Embolization Therapies), Procedure (Tumor Ablation, Tumor Biopsy), Application (Liver Cancer, Lung Cancer), End-user & Regional Forecasts to 2030